GLP-1 Clinical Relevance #47Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic NewsObservationalMetabolic SyndromeSweetenerEndocrinologyAdults with Metabolic DiseaseInsulin ResistanceLipid MetabolismArtificial SweetenerFat AccumulationCardiometabolic RiskNon-Nutritive Sweetener Why...
GLP-1 Clinical Evidence: Insulin Resistance in Childhood Obesity
GLP-1 Clinical Relevance #44Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Longitudinal StudyCohort StudyInsulin ResistanceChildhood ObesityPediatric PatientsEndocrinologyCardiometabolic RiskEpigenetic MarkersDNA MethylationMetabolic Health TrajectoriesPediatric Metabolic DiseaseBiomarker Discovery Why...
GLP-1 Clinical Evidence: Adolescent Metabolic Health
GLP-1 Clinical Relevance #45Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Consensus StatementObservationalAdolescent Metabolic HealthType 2 Diabetes PreventionObesity PreventionPediatric PatientsInsulin ResistanceIncretin EffectEndocrinologyPediatric ObesityMetabolic...
Tirzepatide vs Liraglutide Clinical Research Comparison
GLP-1 Clinical Relevance #47Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical CommentaryObservationalObesityLiraglutideTirzepatideGLP-1 Receptor AgonistEndocrinologyAdults with ObesityWeight ManagementAppetite RegulationFDA Approved TreatmentsHead-to-Head Comparison Why...
GLP-1 Receptor Agonist Evidence: Beyond Obesity & Diabetes
GLP-1 Clinical Relevance #41Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical TrialPhase 3 TrialAlzheimer’s DiseaseSemaglutideNeurologyAdults with Cognitive DeclineCognitive OutcomesNeuroinflammation PathwayOral SemaglutideGLP-1 CNS EffectsNovo Nordisk PipelineEVOKE...